Non-tuberculous mycobacteria disease pre-lung transplantation : A systematic review of the treatment regimens and duration pre- and post-transplant
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved..
BACKGROUND: There is lack of consensus on non-tuberculous mycobacteria pulmonary disease (NTM-PD) treatment regimen and duration in patient listed for lung transplantation (LTx). We conducted a systematic review on treatment regimen and duration pre- and directly post-LTx, for patients with known NTM-PD pre-LTx. Additionally, we searched for risk factors for NTM disease development post-LTx and for mortality.
METHODS: Literature was reviewed on PubMed, Embase and the Cochrane Library, for articles published from inception to January 2022. Individual patient data were sought.
RESULTS: Sixteen studies were included reporting 92 patients. Most frequent used agents were aminoglycosides and macrolides for Mycobacterium abscessus (M. abscessus) and macrolides and tuberculostatic agents for Mycobacterium avium complex (M. avium complex). The median treatment duration pre-LTx was 10 months (IQR 6-17) and 2 months (IQR 2-8) directly post-LTx. Longer treatment duration pre-LTx was observed in children and in patients with M. abscessus. 46% of the patients with NTM-PD pre-LTx developed NTM disease post-LTx, related mortality rate was 10%. Longer treatment duration pre-LTx (p < 0.001) and sputum non-conversion pre-LTx (p = 0.003) were significantly associated with development of NTM-disease post-LTx. Longer treatment duration pre-LTx (p = 0.004), younger age (p < 0.001) and sputum non-conversion (p = 0.044) were risk factors for NTM related death.
CONCLUSIONS: The median treatment duration pre-LTx was 10 months (IQR 6-17) and 2 months (IQR 2-8) directly post-LTx. Patients with longer treatment duration for NTM-PD pre-LTx and with sputum non-conversion are at risk for NTM disease post-LTx and for NTM-related death. Children were particularly at risk for NTM related death.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Transplantation reviews (Orlando, Fla.) - 37(2023), 4 vom: 13. Dez., Seite 100800 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
van Gemert, Johanna P [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Bacterial Agents |
|---|
| Anmerkungen: |
Date Completed 14.11.2023 Date Revised 14.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.trre.2023.100800 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363254730 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363254730 | ||
| 003 | DE-627 | ||
| 005 | 20231226092942.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.trre.2023.100800 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1210.xml |
| 035 | |a (DE-627)NLM363254730 | ||
| 035 | |a (NLM)37832509 | ||
| 035 | |a (PII)S0955-470X(23)00054-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a van Gemert, Johanna P |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Non-tuberculous mycobacteria disease pre-lung transplantation |b A systematic review of the treatment regimens and duration pre- and post-transplant |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.11.2023 | ||
| 500 | |a Date Revised 14.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: There is lack of consensus on non-tuberculous mycobacteria pulmonary disease (NTM-PD) treatment regimen and duration in patient listed for lung transplantation (LTx). We conducted a systematic review on treatment regimen and duration pre- and directly post-LTx, for patients with known NTM-PD pre-LTx. Additionally, we searched for risk factors for NTM disease development post-LTx and for mortality | ||
| 520 | |a METHODS: Literature was reviewed on PubMed, Embase and the Cochrane Library, for articles published from inception to January 2022. Individual patient data were sought | ||
| 520 | |a RESULTS: Sixteen studies were included reporting 92 patients. Most frequent used agents were aminoglycosides and macrolides for Mycobacterium abscessus (M. abscessus) and macrolides and tuberculostatic agents for Mycobacterium avium complex (M. avium complex). The median treatment duration pre-LTx was 10 months (IQR 6-17) and 2 months (IQR 2-8) directly post-LTx. Longer treatment duration pre-LTx was observed in children and in patients with M. abscessus. 46% of the patients with NTM-PD pre-LTx developed NTM disease post-LTx, related mortality rate was 10%. Longer treatment duration pre-LTx (p < 0.001) and sputum non-conversion pre-LTx (p = 0.003) were significantly associated with development of NTM-disease post-LTx. Longer treatment duration pre-LTx (p = 0.004), younger age (p < 0.001) and sputum non-conversion (p = 0.044) were risk factors for NTM related death | ||
| 520 | |a CONCLUSIONS: The median treatment duration pre-LTx was 10 months (IQR 6-17) and 2 months (IQR 2-8) directly post-LTx. Patients with longer treatment duration for NTM-PD pre-LTx and with sputum non-conversion are at risk for NTM disease post-LTx and for NTM-related death. Children were particularly at risk for NTM related death | ||
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Antibiotics | |
| 650 | 4 | |a Cystic fibrosis | |
| 650 | 4 | |a Lung transplantation | |
| 650 | 4 | |a M. abscessus | |
| 650 | 4 | |a M. avium complex | |
| 650 | 4 | |a Non-tuberculous mycobacteria | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Macrolides |2 NLM | |
| 700 | 1 | |a Ravensbergen, Sofanne J |e verfasserin |4 aut | |
| 700 | 1 | |a Verschuuren, Erik A M |e verfasserin |4 aut | |
| 700 | 1 | |a Kerstjens, Huib A M |e verfasserin |4 aut | |
| 700 | 1 | |a Willemse, Brigitte W M |e verfasserin |4 aut | |
| 700 | 1 | |a van Ingen, Jakko |e verfasserin |4 aut | |
| 700 | 1 | |a Hoefsloot, Wouter |e verfasserin |4 aut | |
| 700 | 1 | |a Gan, Tji |e verfasserin |4 aut | |
| 700 | 1 | |a Akkerman, Onno W |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Transplantation reviews (Orlando, Fla.) |d 1992 |g 37(2023), 4 vom: 13. Dez., Seite 100800 |w (DE-627)NLM031132510 |x 1557-9816 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2023 |g number:4 |g day:13 |g month:12 |g pages:100800 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.trre.2023.100800 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2023 |e 4 |b 13 |c 12 |h 100800 | ||